Becton Dickinson and Co vs Bank of New York Mellon Corp — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Bank of New York Mellon Corp trades at $161 (market cap $108.17B). The key difference: Bank of New York Mellon Corp is far larger — about 2.2× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.34%). Which is the better fit depends on your goals.
| BDX | BNY | |
|---|---|---|
Market Cap | $48.93B | $108.17B |
Sector | Health | Financials |
52-Week High | $185.39 | $162.35 |
52-Week Low | $138.62 | $101.00 |
Enterprise Value | $65.03B | — |
Dividend Yield | 2.34% | 1.39% |
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
BNY trades at $157.65, down 0.75% on the day, with a bullish technical signal from moving averages but neutral oscillators. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.46 exceeding expectations. Revenue and net income have shown steady growth, with 2025 revenue at $19.76 billion and net income at $5.55 billion. Recent news highlights BNY's expansion into digital transfer agency capabilities and a strategic collaboration with Galaxy Digital to advance digital asset infrastructure, signaling innovation in fund servicing.
The outlook for BNY is positive, supported by strong earnings performance, a consensus price target of $170.36, and a bullish analyst rating upgrade to Strong Buy by Zacks. Investment opportunities include continued revenue growth and margin expansion. Risks involve high investing cash outflows, competitive pressures in custody banking, and sensitivity to interest rate changes. The stock offers a dividend yield with recent increases, appealing to income-focused investors amid solid fundamentals.
Trailing returns across standard periods
Latest headlines on both assets
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →